Back to Anaplastic Pleomorphic Xanthoastrocytoma

Anaplastic Pleomorphic Xanthoastrocytoma — Clinical Trials

MONDO:08503123 active·1 recruitingLast updated: Mar 15, 2026, 7:53 PM

Trial Landscape

Anaplastic Pleomorphic Xanthoastrocytoma has an emerging clinical trial program, driven by drug treatment and procedure.

Recruiting

Active Trials

By Approach

Drug Treatment3

Procedure1

By Phase

Phase 1

Phase 2

Phase 4

Sponsor Types

Industry2NIH1

Top Sponsors

Jazz Pharmaceuticals

Novartis Pharmaceuticals

Trial Locations

United States3 trials

Puerto Rico1 trial

Argentina1 trial

Australia1 trial

Belgium1 trial

Brazil1 trial

Canada1 trial

Czechia1 trial

Denmark1 trial

Finland1 trial

Trials often recruit across multiple countries, so totals exceed the trial count.

3 Trials

Phase 1Recruiting

NCT04541082

Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Sponsor:Jazz Pharmaceuticals

United StatesStarted: Oct 2020Est. completion: Dec 2026Updated: Dec 2025

Phase 2Active, Not Recruiting

NCT03919071

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Feb 2020Est. completion: Sep 2027Updated: Mar 2026

Phase 4Active, Not Recruiting

NCT03975829

Pediatric Long-Term Follow-up and Rollover Study

Sponsor:Novartis Pharmaceuticals

United StatesStarted: Nov 2019Est. completion: Nov 2026Updated: Feb 2026

Stay informed about clinical trials for Anaplastic Pleomorphic Xanthoastrocytoma.

Follow this disease to get updates when trials open, close, or change status.

Follow This Disease — Free

Already have an account? Sign in to manage your watchlists.

Data sourced from ClinicalTrials.gov via Kisho's automated pipeline. Trials refreshed every 4 hours for monitored diseases.

Last sync: March 15, 2026 at 7:53 PM